Clinical Use of PPARγ Ligands in Cancer

Author(s): Jennifer L. Hatton | Lisa D. Yee

The role of glucose lowering agents on restenosis after percutaneous coronary intervention in patients with diabetes mellitus

Author(s): Lexis Chris | Rahel Braim | Meeder Joan | Zijlstra Felix | van derHorst Iwan

Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes

Author(s): Toshikazu Yamanouchi

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin

Author(s): Bo Ahrén

Effect of glitazones on the progression of coronary artery disease in type 2 diabetes patients

Author(s): Jamison Wyatt | Shailesh Nandish | Rene Oliveros | et al

PPARγ activator, rosiglitazone: Is it beneficial or harmful to the cardiovascular system?

Author(s): Siripong Palee | Siriporn Chattipakorn | Arintaya Phrommintikul | Nipon Chattipakorn

Insulin resistance, insulin sensitization and inflammation in polycystic ovarian syndrome

Author(s): Dhindsa G | Bhatia R | Dhindsa M | Bhatia Vishal

Síntese e atividade antiedematogênica de derivados N-triptofil-5-benzilideno-2,4-tiazolidinadiona e N-triptofil-5-benzilideno-rodanina

Author(s): Góes Alexandre José da Silva | Lima Waldir Tavares de | Nagy Helena Juliana | Alves Antônio José | Faria Antônio Rodolfo de | Lima José Gildo de | Maia Maria Bernadete de Souza

Peroxisome proliferator-activated receptors (PPARs) and ovarian function – implications for regulating steroidogenesis, differentiation, and tissue remodeling

Author(s): Komar Carolyn

Thiazolidinedione induced thyroid associated orbitopathy

Author(s): Lee Seongmu | Tsirbas Angelo | Goldberg Robert | McCann John

Treatment with pioglitazone induced significant, reversible mitral regurgitation

Author(s): Dorkhan Mozhgan | Dencker Magnus | Frid Anders

The Rise and Fall of Rosiglitazone

Author(s): P. Tatti

Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin

Author(s): Stanley S Schwartz

New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin

Author(s): Baptist Gallwitz

Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus

Author(s): Pamela Kushner

Peroxisome proliferator-activated receptor-γ agonists and diabetes: Current evidence and future perspectives

Author(s): Francesco Chiarelli | Daniele Di Marzio

Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes

Author(s): Floris Alexander van de Laar

Pharmacological and non-pharmacological interventions to influence adipose tissue function

Author(s): Westerink Jan | Visseren Frank

The Effects of Thiazolidinediones on Metabolic Complications and Lipodystrophy in HIV-Infected Patients

Author(s): Jussi Sutinen

Antiretroviral-Related Adipocyte Dysfunction and Lipodystrophy in HIV-Infected Patients: Alteration of the PPARγ-Dependent Pathways

Author(s): Martine Caron | Corinne Vigouroux | Jean-Philippe Bastard | Jacqueline Capeau

Implicaciones farmacológicas de los receptores activados por los proliferadores de peroxisomas (PPAR) Pharmacologic implications of peroxisome proliferator activated receptors (PPAR)

Author(s): Sergio Parra | Luis Carlos Mejía Rivera

Retinoid and thiazolidinedione therapies in melanoma: an analysis of differential response based on nuclear hormone receptor expression

Author(s): Klopper Joshua | Sharma Vibha | Berenz Andrew | Hays William | Loi Michele | Pugazhenthi Umarani | Said Sherif | Haugen Bryan

Pharmacologic implications of peroxisome proliferator activated receptors (PPAR) Implicaciones farmacológicas de los receptores activados por los proliferadores de peroxisomas (PPAR)

Author(s): Sergio Parra | Luis Carlos Mejía Rivera

Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes

Author(s): Dorkhan Mozhgan | Dencker Magnus | Stagmo Martin | Groop Leif

Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone

Author(s): Syversen Unni | Stunes Astrid | Gustafsson Björn | Obrant Karl | Nordsletten Lars | Berge Rolf | Thommesen Liv | Reseland Janne

EDITORIAL ADVERSE DRUG REACTIONS: A MULTIFORM PATHOLOGY RESPONSABILITY OF MANY

Author(s): Joan-Ramon Laporte

Insulin and Insulin-Sensitizing Drugs in Neurodegeneration: Mitochondria as Therapeutic Targets

Author(s): Susana Cardoso | Renato Santos | Sonia Correia | Cristina Carvalho | Xiongwei Zhu | Hyoung-Gon Lee | Gemma Casadesus | Mark A. Smith | George Perry | Paula I. Moreira

OUTPATIENT UTILIZATION OF ANTI-DIABETIC DRUGS IN THE SOUTH EASTERN NIGERIA

Author(s): ADIBE M.O. (M.PHARM), PROF. AGUWA C.N. (PHARM D), UKWE C.V. (PH.D), OKONTA J.M. (PH.D), PHARM. UDEOGARANYA P.O (M.PHARM)

Thiazolidinediones enhance vascular endothelial growth factor expression and induce cell growth inhibition in non-small-cell lung cancer cells

Author(s): Yoshizaki Takayuki | Motomura Wataru | Tanno Sachie | Kumei Shima | Yoshizaki Yumiko | Tanno Satoshi | Okumura Toshikatsu

Effects of PPARγ ligands on TGF-β1-induced epithelial-mesenchymal transition in alveolar epithelial cells

Author(s): Tan Xiahui | Dagher Hayat | Hutton Craig | Bourke Jane

Pharmacogenetics of Anti-Diabetes Drugs

Author(s): Johanna K. DiStefano | Richard M. Watanabe

Oral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of ActionOral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of Action

Author(s): Bartolomeo Lorenzati | Chiara Zucco | Sara Miglietta | Federico Lamberti | Graziella Bruno

Lack of effects of pioglitazone on cardiac function in patients with type 2 diabetes and evidence of left ventricular diastolic dysfunction: a tissue doppler imaging study

Author(s): Naka Katerina | Pappas Konstantinos | Papathanassiou Katerina | Papamichael Nikolaos | Kazakos Nikolaos | Kanioglou Chryssanthi | Makriyiannis Demetrios | Katsouras Christos | Liveris Kostas | Tsatsoulis Agathocles | Michalis Lampros

PPAR–gamma: a dagger in endometriosis

Author(s): Amberkar MV | Meena Kumari K | Mor V | Semwal A | Adiga S

Drug Use Evaluation In Diabetic Patients at Out Patient Department Gorakhpur

Author(s): Tripathi Poonam, Pandey Awanish, Pandey Rishabh, Goswamy Shambaditya & Srivatava Rashmi

Incretins and the specific mechanism of action of liraglutide, the first applicable human glucagon-like peptide 1 analog in the treatment of type 2 diabetes

Author(s): Edoardo Mannucci | Caterina Lamanna

Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide

Author(s): Jonathan Pinkney | Thomas Fox | Lakshminarayan Ranganath

Weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experience

Author(s): James E Foley | Jens Jordan

Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes

Author(s): John M Stafford | Tom Elasy

Redefining the role of thiazolidinediones in the management of type 2 diabetes

Author(s): Anthony H Barnett

Pioglitazone and metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy

Author(s): Giuseppe Derosa | Sibilla Anna Teresa Salvadeo

Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus

Author(s): Louise Profit | Paul Chrisp | Carole Nadin

Recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes

Author(s): Peggy Soule Odegard | Anthony DeSantis

A review of exenatide as adjunctive therapy in patients with type 2 diabetes

Author(s): Gisela I Robles | Devada Singh-Franco

Effects of pioglitazone injection into hippocampal CA1 area on spatial learning and memory deficits in rats

Author(s): Amir Farshchi | Golbarg Ghiasi | Gholam-Reza Bahrami | Ali Pourmotabbed | Sayyed-Ershad Nedaee

Diffusion patterns of new anti-diabetic drugs into hospitals in Taiwan: the case of Thiazolidinediones for diabetes

Author(s): Wen Yu-Wen | Huang Weng-Foung | Lee Yue-Chune | Kuo Ken | Tsai Chia-Rung | Tsai Yi-Wen

Effect of pioglitazone treatment on behavioral symptoms in autistic children

Author(s): Boris Marvin | Kaiser Claudia | Goldblatt Allan | Elice Michael | Edelson Stephen | Adams James | Feinstein Douglas

Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System

Author(s): Ramos-Nino Maria | MacLean Charles | Littenberg Benjamin

‘Striking the Right Balance’ in Targeting PPARγ in the Metabolic Syndrome: Novel Insights from Human Genetic Studies

Author(s): Mark Gurnell

Metabolic Functions of Peroxisome Proliferator-Activated Receptor β/δ in Skeletal Muscle

Author(s): Céline Gaudel | Paul A. Grimaldi

Anti-proliferative activity of oral anti-hyperglycemic agents on human vascular smooth muscle cells: thiazolidinediones (glitazones) have enhanced activity under high glucose conditions

Author(s): Little Peter | Osman Narin | de Dios Stephanie | Cemerlang Nelly | Ballinger Mandy | Nigro Julie

Pioglitazone is as effective as dexamethasone in a cockroach allergen-induced murine model of asthma

Author(s): Narala Venkata | Ranga Rajesh | Smith Monica | Berlin Aaron | Standiford Theodore | Lukacs Nicholas | Reddy Raju

Transcriptional Control of Vascular Smooth Muscle Cell Proliferation by Peroxisome Proliferator-Activated Receptor-γ: Therapeutic Implications for Cardiovascular Diseases

Author(s): Florence Gizard | Dennis Bruemmer

PPAR-γ in the Cardiovascular System

Author(s): Sheng Zhong Duan | Christine Y. Ivashchenko | Michael G. Usher | Richard M. Mortensen

Hexarelin Signaling to PPARγ in Metabolic Diseases

Author(s): Annie Demers | Amélie Rodrigue-Way | André Tremblay

Should We Use PPAR Agonists to Reduce Cardiovascular Risk?

Author(s): Jennifer G. Robinson

Rosiglitazone inhibits metastasis development of a murine mammary tumor cell line LMM3

Author(s): Magenta Gabriela | Borenstein Ximena | Rolando Romina | Jasnis María

Rosiglitazone but not losartan prevents Nrf-2 dependent CD36 gene expression up-regulation in an in vivo atherosclerosis model

Author(s): Hernandez-Trujillo Y | Rodriguez-Esparragon F | Macias-Reyes A | Caballero-Hidalgo A | Rodriguez-Perez Jose

Pioglitazone administration alters ovarian gene expression in aging obese lethal yellow mice

Author(s): Brannian John | Eyster Kathleen | Weber Mitch | Diggins Maureen

Regulation of Glial Cell Functions by PPAR-γ Natural and Synthetic Agonists

Author(s): Antonietta Bernardo | Luisa Minghetti

Insulin Sensitizing Pharmacology of Thiazolidinediones Correlates with Mitochondrial Gene Expression rather than Activation of PPARγ

Author(s): Charles W. Bolten | Patrick M. Blanner | William G. McDonald | Nicholas R. Staten | Richard A. Mazzarella | Graciela B. Arhancet | Martin F. Meier | David J. Weiss | Patrick M. Sullivan | Alexander E. Hromockyj | Rolf F. Kletzien | Jerry R. Colca

Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: A randomized controlled trial (the RECORD study)

Author(s): Komajda Michel | Curtis Paula | Hanefeld Markolf | Beck-Nielsen Henning | Pocock Stuart | Zambanini Andrew | Jones Nigel | Gomis Ramon | Home Philip

Effect of Thiazolidinediones on the Erythropoeitic and Germinal Cells in the Male Wistar Rats

Author(s): Syed Imam Rabbani | Kshama Devi | Salma Khanam

Patient factors associated with hemoglobin A1C change with pioglitazone as adjunctive therapy in type 2 Diabetes Mellitus

Author(s): Tran MT | Delate T | Bachmann S

PPARγ Agonists: Potential as Therapeutics for Neovascular Retinopathies

Author(s): Harrihar A. Pershadsingh | David M. Moore

PPAR-γ Thiazolidinedione Agonists and Immunotherapy in the Treatment of Brain Tumors

Author(s): Terry Lichtor | Alessandra Spagnolo | Roberta P. Glick | Douglas L. Feinstein

Activation and Molecular Targets of Peroxisome Proliferator-Activated Receptor-γ Ligands in Lung Cancer

Author(s): Raphael A. Nemenoff | Mary Weiser-Evans | Robert A. Winn

PPARγ and Apoptosis in Cancer

Author(s): Heath A. Elrod | Shi-Yong Sun

PPARs in Alzheimer's Disease

Author(s): Markus P. Kummer | Michael T. Heneka

Mitochondria, PPARs, and Cancer: Is Receptor-Independent Action of PPAR Agonists a Key?

Author(s): Roberto Scatena | Patrizia Bottoni | Bruno Giardina

PPAR Ligands as Potential Modifiers of Breast Carcinoma Outcomes

Author(s): Ancha Baranova

Peroxisome Proliferator-Activated Receptors (PPARs) as Potential Inducers of Antineoplastic Effects in CNS Tumors

Author(s): Lars Tatenhorst | Eric Hahnen | Michael T. Heneka

Peroxisome Proliferator-Activated Receptors in the Modulation of the Immune/Inflammatory Response in Atherosclerosis

Author(s): Ana Z. Fernandez

CXCR4 in Cancer and Its Regulation by PPARγ

Author(s): Cynthia Lee Richard | Jonathan Blay

To Live or to Die: Prosurvival Activity of PPARγ in Cancers

Author(s): Y. Lynn Wang | Qi Miao

PPAR Gamma Activators: Off-Target Against Glioma Cell Migration and Brain Invasion

Author(s): Sebastian Seufert | Roland Coras | Christian Tränkle | Darius P. Zlotos | Ingmar Blümcke | Lars Tatenhorst | Michael T. Heneka | Eric Hahnen

Rosiglitazone Suppresses the Growth and Invasiveness of SGC-7901 Gastric Cancer Cells and Angiogenesis In Vitro via PPARγ Dependent and Independent Mechanisms

Author(s): Qing He | Ruiping Pang | Xin Song | Jie Chen | Huixin Chen | Baili Chen | Pinjin Hu | Minhu Chen

TZDs and Bone: A Review of the Recent Clinical Evidence

Author(s): Ann V. Schwartz

Thiazolidinediones and Fertility in Polycystic Ovary Syndrome (PCOS)

Author(s): Pascal Froment | Philippe Touraine

The Effects of Thiazolidinediones on Metabolic Complications and Lipodystrophy in HIV-Infected Patients

Author(s): Jussi Sutinen

Coenzyme Q10 May be Effective in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)

Author(s): Mohammad Hashemi | Ali Bahari | Gholamreza Bahari Saeid Ghavami

SYNTHESIS AND EVALUATION OF NOVEL THIAZOLIDINEDIONES FOR ANTI INFLAMMATORY ACTIVITY

Author(s): Rekha S | Shantharam U | Vineet chandy

COMPARATIVE STUDY ON EFFECT OF SOLID DISPERSION TECHNIQUES FOR ENHANCEMENT OF DISSOLUTION RATE OF PIOGLITAZONE HCl

Author(s): Mishra Sruti Ranjan | Ellaiah P. | Jena Prabhat Kumar | Nayak Bhabani Shankar | Mishra Gitanjali

Thiazolidinediones on PPARγ: The Roles in Bone Remodeling

Author(s): Wei Wei | Yihong Wan

[5-(3-Indol-1-ylpropoxy)-1H-indol-3-yl] Acetic Acid Enhances Adipocyte Differentiation and Glucose Uptake in 3T3-L1 Cells

Author(s): I. Lee | J. Yu | Y. Yoon | H.J. Gim | S.M. Lee | J.W. Park | R. Jeon | B.H. Park

Pharmacological management of metabolic syndrome and its lipid complications

Author(s): T Binesh Marvasti | Kh Adeli

Management of diabetes across the course of disease: minimizing obesity-associated complications

Author(s): Apovian CM

Investigation of the antibacterial activity of pioglitazone

Author(s): Masadeh MM | Mhaidat NM | Al-Azzam SI | Alzoubi KH

Type 2 diabetes in the wake of Insulin Resistance: Molecular etiology and therapeutics

Author(s): Sonam Chawla* , Deepesh Gupta, Archana Tiwari

Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database

Author(s): Berthet Stephanie | Olivier Pascale | Montastruc Jean-Louis | Lapeyre-Mestre Maryse